Compare ADPT & PCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADPT | PCT |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Environmental Services |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | 2019 | N/A |
| Metric | ADPT | PCT |
|---|---|---|
| Price | $18.46 | $11.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $16.60 | $13.67 |
| AVG Volume (30 Days) | 1.9M | ★ 4.4M |
| Earning Date | 02-05-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $252,754,000.00 | $5,660,000.00 |
| Revenue This Year | $50.86 | N/A |
| Revenue Next Year | $0.53 | $707.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 42.57 | N/A |
| 52 Week Low | $6.26 | $5.40 |
| 52 Week High | $20.76 | $17.37 |
| Indicator | ADPT | PCT |
|---|---|---|
| Relative Strength Index (RSI) | 59.49 | 63.73 |
| Support Level | $16.55 | $10.79 |
| Resistance Level | $19.16 | $12.31 |
| Average True Range (ATR) | 1.00 | 0.78 |
| MACD | 0.18 | 0.21 |
| Stochastic Oscillator | 82.08 | 80.81 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.